Last reviewed · How we verify
Placebo to upadacitinib
This is a placebo control arm in a clinical trial; it contains no active drug and serves as a comparator to upadacitinib's JAK inhibition effects.
At a glance
| Generic name | Placebo to upadacitinib |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used in randomized controlled trials to establish baseline disease progression and distinguish true drug effects from natural disease course or psychological effects. In this Phase 3 trial, placebo recipients receive no active JAK inhibition, allowing researchers to measure the efficacy and safety of upadacitinib (an active JAK1/JAK2 inhibitor) against a control group.
Approved indications
Common side effects
Key clinical trials
- Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study. (PHASE2)
- Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (PHASE3)
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (PHASE3)
- A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (PHASE3)
- Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (PHASE3)
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to upadacitinib CI brief — competitive landscape report
- Placebo to upadacitinib updates RSS · CI watch RSS
- AbbVie portfolio CI